《大行報告》瑞信:廣汽(02238.HK)3月銷量按年升31% 顯著優於行業平均跌11%
瑞信發表研究報告指出,廣汽集團(02238.HK)3月銷量按年升31%至22.75萬輛,顯著優於行業平均跌11%;廣汽首季銷量按年增長22.5%至60.82萬輛,高於集團全年銷售額按年增長15%的目標。因此,該行預期廣汽首季純利按年升7%至25億元人民幣,按季增長23%。
此外,該行指廣汽AION電動車營運月度銷量升至創紀錄的2.03萬輛,目標全年銷量達18萬至20萬輛,至2025年可達60萬輛。
瑞信維持對廣汽的「跑贏大市」評級,目標價續為10.2元不變,預期在日本合資公司的強勢周期下,集團合資公司表現將持續改善,而本土品牌營運將走出轉型陣痛期。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.